Zymeworks Inc
1385 West 8th Avenue
Suite 540
Vancouver
British Columbia
V6H 3V9
Canada
Tel: 604-678-1388
Website: http://www.zymeworks.com/
Email: info@zymeworks.com
About Zymeworks Inc
Established in 2003 with offices in Vancouver, BC and Seattle, WA, Zymeworks is a fast-growing, clinical-stage biotechnology company dedicated to the research, development and commercialization of best-in-class therapeutic bispecific antibodies and antibody drug conjugates for the treatment of cancer, autoimmune and inflammatory diseases. Zymeworks is proud to have active collaborations with Merck, Eli Lilly, Celgene, GlaxoSmithKline, Daiichi-Sankyo, Johnson & Johnson, Leo Pharma and BeiGene and is committed to making a meaningful difference in the lives of patients everywhere.
200 articles with Zymeworks Inc
-
Zymeworks Provides Corporate Update and Reports First Quarter 2022 Financial Results
5/4/2022
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today reported financial results for the first quarter ended March 31, 2022.
-
Dianthus Therapeutics, Enavate Sciences and CytoTronics were all launched with this recent wave of investor funding. For that and more, continue reading.
-
ALL BLUE CAPITAL ANNOUNCES LEADERSHIP TO SUPPORT PROPOSED ACQUISITION OF ZYMEWORKS, INC.
5/3/2022
All Blue Capital ("AB"), a global investment firm, today announced that biopharmaceutical industry leader and expert, Alan Barge, MD, has agreed to advise the firm as Oncology Drug Development Advisor.
-
Zymeworks Announces Participation in Upcoming Investor Conferences - May 02, 2022
5/2/2022
Zymeworks Inc. announced that management will participate in an upcoming investor conference: H.C. Wainwright Global Investment Conference.
-
A roundup of last week's top clinical trial updates and news.
-
Zymeworks received an unsolicited, non-binding acquisition offer from global investment firm All Blue Capital. All Blue is offering $10.50 per share for a total of $773 million in cash.
-
Zymeworks Reports Last Patient Enrolled in Pivotal Study of Zanidatamab in Treatment of HER2-Expressing Late-Line Biliary Tract Cancer
4/28/2022
Zymeworks Inc. today announced that it has completed enrollment in its global HERIZON-BTC-01 pivotal clinical trial evaluating the antitumor activity of zanidatamab monotherapy.
-
Zymeworks Announces Presentations at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
4/27/2022
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced, in conjunction with its Asia Pacific partner BeiGene, the acceptance of two abstracts for poster presentations at the upcoming 2022 ASCO Annual Meeting taking place virtually and in Chicago, IL from June 3 – 7, 2022.
-
Zymeworks to Host First Quarter 2022 Results Conference Call
4/19/2022
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that management will report its first quarter 2022 financial results after market close on May 4th, 2022.
-
Atreca Announces Expansion of Preclinical Pipeline
4/5/2022
Atreca, Inc. announced a licensing agreement with Zymeworks Inc. to utilize their ZymeLink™ technology to develop novel antibody-drug conjugates and declared ATRC-301, an ADC targeting a novel epitope on EphA2, as the Company’s next clinical candidate.
-
Zymeworks Announces Participation in Upcoming Investor Conferences - Apr 01, 2022
4/1/2022
Zymeworks Inc., a clinical-stage biopharmaceutical company developing next-generation multifunctional biotherapeutics, announced that management will participate in upcoming investor conferences: Wells Fargo 2022 Biotech Forum.
-
Zymeworks Announces Participation in Upcoming Investor Conferences
3/3/2022
Zymeworks Inc. today announced that management will participate in upcoming investor conferences during March.
-
Zymeworks Provides Corporate Update and Reports Year-End 2021 Financial Results
2/24/2022
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing next-generation multifunctional biotherapeutics, today reported financial results for the year ended December 31, 2021 and provided a summary of recent business highlights.
-
Zymeworks to Host Fourth Quarter and Full Year 2021 Results Conference Call
2/8/2022
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that management will report its fourth quarter and full year 2021 financial results after market close on February 24th, 2022.
-
Zymeworks Announces Participation in Upcoming Investor Conferences - Feb 03, 2022
2/3/2022
Zymeworks Inc. announced that management will participate in upcoming investor conferences.
-
Zymeworks Announces Closing of Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
1/31/2022
Zymeworks Inc. today announced the closing of its previously announced underwritten public offering of 11,035,000 common shares.
-
Zymeworks Announces Pricing of $100.0 Million Public Offering
1/27/2022
Zymeworks Inc., a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, announced the pricing of its underwritten public offering of 9,160,000 common shares and, in lieu of common shares to certain investors, pre-funded warrants to purchase up to 3,340,000 common shares.
-
Zymeworks Announces Proposed Public Offering
1/26/2022
Zymeworks Inc., a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, announced that it has commenced an underwritten public offering of its common shares and, in lieu of common shares to certain investors, pre-funded warrants to purchase its common shares.
-
As part of a company-wide workforce reduction, it will cut its employee headcount by at least 25% by the end of the year, and 50% of its senior management team are leaving the company.
-
Zymeworks Provides Corporate Update on Key Strategic Priorities and Outlook for 2022
1/19/2022
Zymeworks Inc., a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, provided a corporate update on its key strategic priorities for 2022 and 2023 in addition to confirming its upcoming clinical development milestones for zanidatamab and ZW49.